CRIP2

Summary

CRIP2 (cysteine rich protein 2, HGNC:2361) is a protein-coding gene on chromosome 14q32.33, encoding Cysteine-rich protein 2 (P52943).

This gene encodes a putative transcription factor with two LIM zinc-binding domains. The encoded protein may participate in the differentiation of smooth muscle tissue. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 1397 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 64 total
• GTEx eGene: eQTL in 19 tissues, sQTL in 5 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.55 (unconstrained)
• MANE Select transcript: NM_001312
• Notable: 64 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2361
Approved symbol	CRIP2
Name	cysteine rich protein 2
Location	14q32.33
Locus type	gene with protein product
Status	Approved
Aliases	CRP2, ESP1
Ensembl gene	ENSG00000182809
Ensembl biotype	protein_coding
OMIM	601183
Entrez	1397

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 21 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

MANE Select: ENST00000329146

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 5, TSL 3: 4

ENST00000329146, ENST00000483017, ENST00000538259, ENST00000547643, ENST00000548309, ENST00000548923, ENST00000548989, ENST00000550577, ENST00000551738, ENST00000551836, ENST00000552643, ENST00000852172, ENST00000852173, ENST00000852174, ENST00000852175, ENST00000942976, ENST00000942977, ENST00000942978, ENST00000942979, ENST00000942980, ENST00000942981, ENST00000987978, ENST00001016561, ENST00001016562, ENST00001016566, ENST00001092906, ENST00001092907, ENST00001092908, ENST00001127141, ENST00001139766

RefSeq mRNA: 3 — MANE Select: NM_001312 NM_001270837, NM_001270841, NM_001312

CCDS: CCDS10003, CCDS59246

Canonical transcript exons

ENST00000329146 — 8 exons

Exon	Start	End
ENSE00001305445	105474821	105474905
ENSE00002338634	105479586	105480162
ENSE00003551850	105479436	105479493
ENSE00003567190	105478731	105478871
ENSE00003571158	105478266	105478360
ENSE00003626622	105479125	105479219
ENSE00003635215	105478450	105478507
ENSE00003650733	105478979	105479047

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 99.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.8614 / max 691.3117, expressed in 1527 samples.

Highest expression (Bgee): apex of heart, atrium auricular region, coronary artery, cardiac atrium, popliteal artery.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CRIP2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 19 tissues and its splicing (sQTL) in 5 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 24 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Heart Left Ventricle	eqtl	3.6e-06	+0.24	14:105451479:G:C
Esophagus Mucosa	eqtl	4.1e-06	-0.77	14:105697231:G:A
Brain Cerebellum	eqtl	4.6e-05	+1.45	14:104995206:CTCTG:C
Whole Blood	eqtl	5.2e-05	+0.19	14:105451479:G:C
Brain Cerebellar Hemisphere	eqtl	7.7e-05	-0.84	14:105730502:G:C
Cells Cultured fibroblasts	eqtl	1.6e-04	-0.29	14:105476010:C:G
Nerve Tibial	eqtl	8.8e-04	-0.39	14:105489681:G:A
Heart Atrial Appendage	eqtl	1.4e-03	+0.15	14:105464069:G:A
Lung	sqtl	3.0e-03	+0.69	14:105477342:G:A
Artery Tibial	eqtl	6.5e-03	+0.17	14:105486987:C:T
Cells EBV-transformed lymphocytes	eqtl	6.8e-03	+1.24	14:105906937:C:T
Artery Aorta	eqtl	8.4e-03	+0.28	14:105473030:GAGCAAGCCCCACAGGT:G
Bladder	eqtl	1.2e-02	-1.89	14:104502832:T:A
Colon Sigmoid	eqtl	1.9e-02	+0.14	14:105451479:G:C
Brain Caudate basal ganglia	eqtl	2.1e-02	+0.23	14:105451479:G:C
Breast Mammary Tissue	sqtl	2.3e-02	+0.66	14:105477342:G:A
Esophagus Mucosa	sqtl	2.9e-02	+0.86	14:105628392:A:C
Esophagus Muscularis	eqtl	3.0e-02	-0.44	14:105400279:C:T
Lung	eqtl	3.5e-02	+0.12	14:105464069:G:A
Skin Sun Exposed Lower leg	eqtl	3.6e-02	+0.12	14:105487689:T:C

FANTOM5 promoters

showing 10 of 15 alternative TSS:

Promoter ID	TPM avg	Samples expressed
141910	32.9192	1497
141909	0.6983	293
141919	0.5811	346
141911	0.3241	163
141916	0.3149	177
141917	0.2570	125
207390	0.2444	118
141918	0.2172	114
141913	0.1538	84
141908	0.0559	7

Top tissues by expression

showing 100 of 288 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.78	gold quality
right atrium auricular region	UBERON:0006631	99.67	gold quality
right coronary artery	UBERON:0001625	99.56	gold quality
cardiac atrium	UBERON:0002081	99.55	gold quality
popliteal artery	UBERON:0002250	99.43	gold quality
tibial artery	UBERON:0007610	99.42	gold quality
ascending aorta	UBERON:0001496	99.40	gold quality
descending thoracic aorta	UBERON:0002345	99.40	gold quality
thoracic aorta	UBERON:0001515	99.39	gold quality
right uterine tube	UBERON:0001302	99.38	gold quality
left coronary artery	UBERON:0001626	99.38	gold quality
aorta	UBERON:0000947	99.36	gold quality
heart left ventricle	UBERON:0002084	99.32	gold quality
cardiac ventricle	UBERON:0002082	99.25	gold quality
coronary artery	UBERON:0001621	99.20	gold quality
adenohypophysis	UBERON:0002196	99.06	gold quality
lower esophagus	UBERON:0013473	98.96	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.96	gold quality
heart	UBERON:0000948	98.93	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.89	gold quality
right lung	UBERON:0002167	98.74	gold quality
tibial nerve	UBERON:0001323	98.69	gold quality
metanephros cortex	UBERON:0010533	98.62	gold quality
left uterine tube	UBERON:0001303	98.61	gold quality
anterior cingulate cortex	UBERON:0009835	98.60	gold quality
cortical plate	UBERON:0005343	98.59	gold quality
right lobe of thyroid gland	UBERON:0001119	98.56	gold quality
lower esophagus mucosa	UBERON:0035834	98.56	gold quality
cingulate cortex	UBERON:0003027	98.55	gold quality
mucosa of stomach	UBERON:0001199	98.50	gold quality
endometrium epithelium	UBERON:0004811	98.48	gold quality
right frontal lobe	UBERON:0002810	98.47	gold quality
left lobe of thyroid gland	UBERON:0001120	98.46	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.39	gold quality
upper lobe of left lung	UBERON:0008952	98.39	gold quality
omental fat pad	UBERON:0010414	98.26	gold quality
peritoneum	UBERON:0002358	98.17	gold quality
body of uterus	UBERON:0009853	98.07	gold quality
endocervix	UBERON:0000458	98.01	gold quality
ganglionic eminence	UBERON:0004023	97.96	gold quality
pituitary gland	UBERON:0000007	97.93	gold quality
prefrontal cortex	UBERON:0000451	97.92	gold quality
upper lobe of lung	UBERON:0008948	97.90	gold quality
heart right ventricle	UBERON:0002080	97.86	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.76	gold quality
skin of leg	UBERON:0001511	97.67	gold quality
minor salivary gland	UBERON:0001830	97.66	gold quality
amygdala	UBERON:0001876	97.59	gold quality
skin of abdomen	UBERON:0001416	97.51	gold quality
nucleus accumbens	UBERON:0001882	97.46	gold quality
thyroid gland	UBERON:0002046	97.44	gold quality
myocardium	UBERON:0002349	97.44	gold quality
esophagus	UBERON:0001043	97.30	gold quality
caudate nucleus	UBERON:0001873	97.19	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.09	gold quality
ectocervix	UBERON:0012249	97.09	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.06	gold quality
right testis	UBERON:0004534	97.02	gold quality
Brodmann (1909) area 10	UBERON:0013541	96.95	gold quality
left testis	UBERON:0004533	96.93	gold quality
vena cava	UBERON:0004087	96.85	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.69	gold quality
left ventricle myocardium	UBERON:0006566	96.68	gold quality
blood vessel layer	UBERON:0004797	96.54	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.18	gold quality
frontal pole	UBERON:0002795	96.17	gold quality
putamen	UBERON:0001874	96.03	gold quality
ventricular zone	UBERON:0003053	96.03	gold quality
esophagus mucosa	UBERON:0002469	95.96	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.91	gold quality
neocortex	UBERON:0001950	95.84	gold quality
spleen	UBERON:0002106	95.81	gold quality
frontal cortex	UBERON:0001870	95.78	gold quality
mouth mucosa	UBERON:0003729	95.64	gold quality
zone of skin	UBERON:0000014	95.61	gold quality
hypothalamus	UBERON:0001898	95.56	gold quality
gall bladder	UBERON:0002110	95.53	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.48	gold quality
small intestine Peyer’s patch	UBERON:0003454	95.25	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.09	gold quality
body of stomach	UBERON:0001161	95.04	gold quality
spinal cord	UBERON:0002240	94.93	gold quality
sural nerve	UBERON:0015488	94.66	gold quality
middle frontal gyrus	UBERON:0002702	94.51	gold quality
saphenous vein	UBERON:0007318	94.43	gold quality
saliva-secreting gland	UBERON:0001044	94.30	gold quality
forebrain	UBERON:0001890	94.29	gold quality
right ovary	UBERON:0002118	94.25	gold quality
telencephalon	UBERON:0001893	94.13	gold quality
cerebral cortex	UBERON:0000956	94.03	gold quality
mucosa of transverse colon	UBERON:0004991	93.95	gold quality
testis	UBERON:0000473	93.84	gold quality
transverse colon	UBERON:0001157	93.83	gold quality
colonic epithelium	UBERON:0000397	93.60	gold quality
pharyngeal mucosa	UBERON:0000355	93.42	gold quality
central nervous system	UBERON:0001017	92.98	gold quality
brain	UBERON:0000955	92.91	gold quality
small intestine	UBERON:0002108	92.90	gold quality
stomach	UBERON:0000945	92.89	gold quality
adipose tissue	UBERON:0001013	92.71	gold quality

Single-cell (SCXA)

Detected in 28 experiment(s), a significant marker in 25.

Experiment	Marker?	Max mean expression
E-MTAB-8221	yes	1672.08
E-MTAB-9906	yes	1376.31
E-MTAB-8410	yes	1014.03
E-MTAB-7407	yes	455.76
E-MTAB-10855	yes	412.62
E-MTAB-8911	yes	263.37
E-MTAB-10287	yes	92.23
E-HCAD-1	yes	55.69
E-GEOD-134144	yes	51.39
E-HCAD-11	yes	50.80
E-GEOD-135922	yes	45.57
E-MTAB-8142	yes	43.76
E-HCAD-10	yes	41.83
E-CURD-46	yes	41.71
E-MTAB-6701	yes	38.05

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Heart muscle	tissue	555.1	not detected
Pituitary gland	tissue	188.5
Frontal cortex	tissue	162.3
Caudate putamen	tissue	153.7
Hippocampus	tissue	146.1	not detected
Spinal cord	tissue	130.6
Nucleus accumbens	tissue	125.3
Locus coeruleus	tissue	120.5
Vagina	tissue	109.8	not detected
Cerebral cortex	tissue	98.2	low
Motor cortex	tissue	98.2
Prefrontal cortex	tissue	95.0
Lung	tissue	89.5	high
Skin 1	tissue	86.3	not detected
Postcentral gyrus	tissue	86.2
Adipose tissue	tissue	86.1	not detected
Retrosplenial cortex	tissue	85.2
Substantia nigra	tissue	84.9
Retrosplenial and cingulate cortex	tissue	84.6
Somatosensory cortex	tissue	79.4
Insular cortex	tissue	79.2
Basal ganglia	tissue	76.2	not detected
Superior colliculi	tissue	75.9
Hippocampal formation	tissue	75.5
Entorhinal cortex	tissue	75.5
Fallopian tube	tissue	75.1	medium
Putamen	tissue	73.4
Thalamus	tissue	73.4
Temporal cortex	tissue	72.8
Pons	tissue	72.5
Occipital cortex	tissue	72.1
Seminal vesicle	tissue	68.8	medium
Midbrain	tissue	67.4
Choroid plexus	tissue	66.7
Medulla oblongata	tissue	66.0
Esophagus	tissue	62.6	medium
Salivary gland	tissue	58.1	low
Urinary bladder	tissue	57.6	high
Hypothalamus	tissue	55.6
Septum	tissue	53.2
Ventral forebrain	tissue	52.8
Cervix	tissue	50.1	medium
Placenta	tissue	46.6	medium
Spleen	tissue	46.3	not detected
Skeletal muscle	tissue	45.0	not detected
Gallbladder	tissue	45.0	medium
Stomach 1	tissue	43.1	not detected
Endometrium 1	tissue	42.8	medium
Thyroid gland	tissue	42.8	low
Periaqueductal gray	tissue	42.6
Amygdala	tissue	41.8
Tongue	tissue	39.8
Adrenal gland	tissue	38.1	not detected
Corpus callosum	tissue	37.9
Pancreas	tissue	37.2	medium
Kidney	tissue	34.9	medium
Epididymis	tissue	34.4	medium
Olfactory bulb	tissue	33.4
Breast	tissue	30.0	medium
Smooth muscle	tissue	29.9	not detected

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Blood vessel (641.8), Ventromedial nucleus (208.2), Arcuate nucleus (197.7), Posterior cingulate cortex (169.0), Temporo-occipital transitional zone (167.9).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting CRIP2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

9 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-6767-5P	90.00	62.41	97
HSA-MIR-542-5P	87.47	60.42	76

Functional genomics

gnomAD constraint: pLI 6.91e-13, LOEUF 1.55, missense Z -3.35 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000329146 — one region, missense o/e 1.29.

Literature-anchored findings (GeneRIF, showing 8)

• Function of avian CRIP2 in smooth muscle differentiation (PMID:12530967)
• These findings suggest that ADAM19 autolysis is activated by lipopolysaccharide and that ADAM19 promotes the secretion of CRIP2. (PMID:20460109)
• CRIP2 acts as a transcription repressor of the NF-kappaB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis (PMID:21540330)
• CRIP2 expression is down-regulated in ESCC tissues and cell lines. (PMID:22154084)
• High CRP2 expression is associated with breast cancer cell invasion and metastasis. (PMID:26883198)
• HOXA9 inhibits HIF1A-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development. (PMID:29662084)
• APEX2-based Proximity Labeling of Atox1 Identifies CRIP2 as a Nuclear Copper-binding Protein that Regulates Autophagy Activation. (PMID:34550632)
• Prognosis biomarker and potential therapeutic target CRIP2 associated with radiosensitivity in NSCLC cells. (PMID:34773852)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	crip2l	ENSDARG00000033201
danio_rerio	crip2	ENSDARG00000070670
mus_musculus	Crip2	ENSMUSG00000006356
rattus_norvegicus		ENSRNOG00000063576

Paralogs (20): FHL1 (ENSG00000022267), LMO3 (ENSG00000048540), LHX5 (ENSG00000089116), ZFHX4 (ENSG00000091656), LHX2 (ENSG00000106689), LHX6 (ENSG00000106852), LHX3 (ENSG00000107187), LHX4 (ENSG00000121454), LMO2 (ENSG00000135363), ZFHX2 (ENSG00000136367), LMX1B (ENSG00000136944), ZFHX3 (ENSG00000140836), LMO4 (ENSG00000143013), LHX9 (ENSG00000143355), CRIP3 (ENSG00000146215), LHX8 (ENSG00000162624), LMX1A (ENSG00000162761), LMO1 (ENSG00000166407), CRIP1 (ENSG00000213145), LHX1 (ENSG00000273706)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1915587) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 2 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal mechanical nociception	1
abnormal nociception after inflammation	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Gallus gallus	P67966	100.0%	Diamond
Coturnix japonica	P67967	100.0%	Diamond
Bos taurus	Q32LE9	100.0%	Diamond
Pongo abelii	Q5RCT4	99.5%	Diamond
Arabidopsis thaliana	O04193	85.0%	Diamond
Drosophila melanogaster	Q24400	76.7%	Diamond
Oryza sativa Japonica Group	Q7F9R9	64.7%	Diamond
Dictyostelium discoideum	Q9BIW5	45.2%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
PACS2	protein-coding	23241
TEX22	protein-coding	647310
MTA1	protein-coding	9112
CRIP1	protein-coding	1396
TEDC1	protein-coding	283643
TMEM121	protein-coding	80757
MTA1-DT	ncRNA	100507437

Protein

Protein identifiers

Cysteine-rich protein 2 — P52943 (reviewed: P52943)

Alternative names: Protein ESP1

All UniProt accessions (3): P52943, H0YFA4, H0YHD8

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with TGFB1I1.

Tissue specificity. Widespread tissue expression; highest levels in the heart.

Isoforms (2)

UniProt ID	Names	Canonical?
P52943-1	1	yes
P52943-2	2

RefSeq proteins (3): NP_001257766, NP_001257770, NP_001303* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001781	Znf_LIM	Domain

Pfam: PF00412

UniProt features (18 total): strand 5, modified residue 4, turn 3, domain 2, chain 1, helix 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

1 structures by resolution:

PDB	Title	Method	Resolution (Å)
2CU8	Solution structure of the LIM domain of human Cysteine-rich protein 2	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P52943-F1	73.78	0.06

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoli; nucleoplasm; plasma membrane

Antibody reliability (HPA): IH approved · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4)

Type	Positions
N6-acetyllysine	23, 138, 144
Phosphoserine	104

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 199 (showing top): MODULE_97, HORIUCHI_WTAP_TARGETS_DN, MYOGENIN_Q6, MODULE_169, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, GCANCTGNY_MYOD_Q6, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, MODULE_182, CAGCTG_AP4_Q5, EFC_Q6, UEDA_PERIFERAL_CLOCK, KESHELAVA_MULTIPLE_DRUG_RESISTANCE, GROSS_HYPOXIA_VIA_ELK3_UP, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): cell cortex (GO:0005938)

GO top-level categories

5 GO namespaces:

Category	Terms
transition metal ion binding	1
binding	1
cation binding	1
cytoplasm	1
cell periphery	1

Protein interactions and networks

STRING

showing 16 of 582 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CRIP2	CLBA1	Q96F83	467
CRIP2	STEEP1	Q9H5V9	438
CRIP2	NDRG4	Q9ULP0	428
CRIP2	NUDT14	O95848	380
CRIP2	GLIPR2	Q9H4G4	370
CRIP2	LRWD1	Q9UFC0	359
CRIP2	SYNE2	Q8WXH0	358
CRIP2	PLD4	Q96BZ4	349
CRIP2	PHPT1	Q9NRX4	328
CRIP2	MCCC2	Q9HCC0	324
CRIP2	SFXN2	Q96NB2	324
CRIP2	HMG20B	Q9P0W2	317
CRIP2	TGM2	P21980	317
CRIP2	TM4SF1	P30408	313
CRIP2	VWA5B1	Q5TIE3	313
CRIP2	VWA5B2	Q8N398	313

IntAct

Human interaction partners of CRIP2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

13 partners by confidence:

Partner	Interaction type	MIscore	Records
ERBB2	physical association	0.550	1
RELA	physical association	0.400	2
ATP1B1	physical association	0.370	1
ATXN1	physical association	0.370	1
GADD45G	physical association	0.370	1
KLF10	physical association	0.370	1
OSGEP	physical association	0.370	1
PCYT2	physical association	0.370	1
SMN1	physical association	0.370	1
SPRY2	physical association	0.370	1
TK1	physical association	0.370	1
AEN	association	0.350	1
ATN1	physical association	0.000	1

BioGRID (60 interactions; top human partners by supporting records): APP (Affinity Capture-MS; 2 records), BAG3 (Affinity Capture-MS; 2 records), PPT1 (Affinity Capture-MS; 2 records), SARNP (Affinity Capture-MS; 2 records), WDR5 (Affinity Capture-MS; 2 records), ACOT6 (Affinity Capture-MS), ADK (Co-fractionation), AEN (Affinity Capture-MS), ATG16L1 (Proximity Label-MS), ATN1 (Two-hybrid), ATP1B1 (Two-hybrid), ATXN1 (Two-hybrid), CDC42 (Reconstituted Complex), CUL3 (Affinity Capture-MS), DDX58 (Affinity Capture-RNA)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
PRKG1	unknown	CRIP2	phosphorylation

Disease & clinical

Genetic variants

Variant evidence for CRIP2: 64 ClinVar records (0 pathogenic / likely pathogenic).

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	4
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 44 predictions of 626):

Position(s)	Effect	Δscore	Sites
14:105474906–105474907	donor_loss	1.0000	5
14:105478259	acceptor_gain	1.0000
14:105479220–105479221	donor_loss	1.0000	5
14:105479226	donor_gain	1.0000
14:105478264–105478265	acceptor_loss	0.9900	6
14:105478361–105478362	donor_loss	0.9900	5
14:105478508–105478509	donor_loss	0.9900	5
14:105478729–105478730	acceptor_loss	0.9900	5
14:105478872–105478873	donor_loss	0.9900	5
14:105478977–105478978	acceptor_loss	0.9900	6

AlphaMissense

787 missense substitutions predicted likely pathogenic (of 1,349 scored), across 151 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
H26	8	0.998	0.999
H147	8	0.998	0.999
H165	8	0.987	0.998
H44	8	0.984	0.998
F14	8	0.956	0.997
F135	8	0.952	0.997
H168	8	0.952	0.997
H47	8	0.948	0.996
H175	8	0.915	0.990
H54	8	0.894	0.985
D24	8	0.878	0.957
W25	7	0.999	1.000
C29	7	0.999	1.000
C32	7	0.999	1.000
C53	7	0.999	1.000
C57	7	0.999	1.000
C126	7	0.999	1.000
W146	7	0.999	1.000
C150	7	0.999	1.000
C153	7	0.999	1.000

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	3.02e-05
Liver Hepatocellular Carcinoma (validation)	favorable	4.52e-05

Disease associations

OMIM: gene MIM:601183 | disease phenotypes:

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, affects cotreatment, decreases methylation, decreases expression, increases expression	4
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression, affects expression (+1 more)	4
Tobacco Smoke Pollution	decreases expression, affects expression	3
Valproic Acid	affects expression, increases expression, increases methylation	3
Cyclosporine	decreases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Cisplatin	affects cotreatment, increases expression	2
Doxorubicin	affects expression	2
Smoke	decreases expression, increases abundance, increases expression	2
2,4,6-tribromophenol	decreases expression	1
propionaldehyde	increases expression	1
decabromobiphenyl ether	decreases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
tetrahydropalmatine	decreases expression	1
arsenite	affects binding, decreases reaction	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
tetrabromobisphenol A	decreases expression	1
potassium chromate(VI)	decreases expression	1
monomethylarsonous acid	increases expression	1
nutlin 3	affects cotreatment, increases expression, increases secretion	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Bortezomib	decreases expression	1

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.